文献速递神经核医学肿瘤 PET/CT

工程化抗体:脑部PET的新可能?

Engineered antibodies: new possibilities for brain PET?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-07-24

综述探讨基于抗体的放射性配体用于脑部PET显像,以可视化脑内靶点。重点介绍经改造为双特异性格式、可经转铁蛋白受体1(TfR1)介导的转胞吞作用穿越血脑屏障的抗体,在转基因小鼠中呈现脑摄取、药代动力学及靶点结合与显像能力的差异。结论认为该策略对传统小分子配体难以靶向的脑内分子具有前景,但面临核素半衰期与药代匹配及向人体转化等挑战。

要点

  • 抗体经TfR1介导转胞吞改造为双特异性格式后可进入脑组织。
  • 此类抗体配体在转基因小鼠中脑摄取、药代和靶点显像能力存在差异。
  • 核素半衰期与配体药代匹配及人体转化是主要挑战。

核心结论

  • 基于经受体介导转胞吞穿越血脑屏障的双特异性抗体的脑PET显像,是特异性可视化传统小分子配体难以靶向的脑内分子的有前景方法。

研究设计与样本

  • 本文为综述,围绕基于抗体的放射性配体用于可视化脑内靶点的开发进行汇总。

主要发现

  • 多种此类抗体配体已被开发,在转基因小鼠中显示脑摄取、药代动力学及靶点结合与显像能力的差异。

关键数值与推荐

  • 抗体需改造为双特异性格式,以具备经转铁蛋白受体1(TfR1)介导的转胞吞作用进入脑并接触病理蛋白(如β-淀粉样蛋白)的能力。

临床怎么用

  • 脑PET可采用经受体介导转胞吞改造的双特异性抗体,用于靶向脑内难以用小分子配体可视化的分子。

局限性

  • 面临放射性核素半衰期与配体药代动力学特征的时间匹配问题,以及向人体应用转化等挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Almost 50 million people worldwide are affected by Alzheimer's disease (AD), the most common neurodegenerative disorder. Development of disease-modifying therapies would benefit from reliable, non-invasive positron emission tomography (PET) biomarkers for early diagnosis, monitoring of disease progression, and assessment of therapeutic effects. Traditionally, PET ligands have been based on small molecules that, with the right properties, can penetrate the blood-brain barrier (BBB) and visualize targets in the brain. Recently a new class of PET ligands based on antibodies have emerged, mainly in applications related to cancer. While antibodies have advantages such as high specificity and affinity, their passage across the BBB is limited. Thus, to be used as brain PET ligands, antibodies need to be modified for active transport into the brain. Here, we review the development of radioligands based on antibodies for visualization of intrabrain targets. We focus on antibodies modified into a bispecific format, with the capacity to undergo transferrin receptor 1 (TfR1)-mediated transcytosis to enter the brain and access pathological proteins, e.g. amyloid-beta. A number of such antibody ligands have been developed, displaying differences in brain uptake, pharmacokinetics, and ability to bind and visualize the target in the brain of transgenic mice. Potential pathological changes related to neurodegeneration, e.g. misfolded proteins and neuroinflammation, are suggested as future targets for this novel type of radioligand. Challenges are also discussed, such as the temporal match of radionuclide half-life with the ligand's pharmacokinetic profile and translation to human use. In conclusion, brain PET imaging using bispecific antibodies, modified for receptor-mediated transcytosis across the BBB, is a promising method for specifically visualizing molecules in the brain that are difficult to target with traditional small molecule ligands.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sehlin D, Syvänen S. Engineered antibodies: new possibilities for brain PET? Eur J Nucl Med Mol Imaging. 2019. PMID: 31342134. doi:10.1007/s00259-019-04426-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。